Poly-γ-Glutamic Acid for Health & Longevity - Quick Reference Sheet

Poly-γ-Glutamic Acid for Health & Longevity

Created on 09/24/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Poly-γ-glutamic acid, the sticky substance in fermented soybeans, is a dietary supplement studied for immune, calcium and blood-sugar effects. Evidence is small and largely company-generated: one controlled study saw more early precancerous changes of the cervix clear; short studies suggest it may help calcium absorption and soften blood-sugar rises after starchy meals. The main risk is a rare, serious allergic reaction starting hours after a dose. Long-term value remains uncertain. (Full Review)

Protocol

Cervical-lesion protocol
1,500 mg/day orally
4 weeks, with reassessment at 12 weeks
Immune protocol
500 mg twice daily
High-molecular-mass (about 2,000 kilodaltons), dissolved in water, 12 hours apart, for 8 weeks
Time of day
Mealtime or morning
Mealtime for calcium and glucose goals; morning in the first weeks keeps any delayed allergic reaction within waking hours
Time to effect
Cervical-lesion regression
12 weeks
Assessed at week 12, eight weeks after the 4-week course ended
Glucose and calcium
Same meal
Effects occur with the same meal
Natural killer cell activity
4–8 weeks
Changed within 4–8 weeks in one trial

Benefits

Contraindications
  • Natto allergy, or a positive skin-prick or basophil activation test to γ-PGA
  • Anaphylaxis after eating jellyfish, or systemic reactions to jellyfish stings
  • Solid-organ or stem-cell transplant recipients on maintenance immunosuppression
  • Pregnancy and breastfeeding (no safety data)
  • CIN 2 or worse (high-grade lesions) using γ-PGA in place of surgical removal or destruction of the lesion
  • Systemic mastocytosis (overactive allergy-cell disorder) or idiopathic (unexplained) anaphylaxis
  • Hypercalcemia (serum calcium above 10.5 mg/dL) when using calcium-γ-PGA products
Key Interactions
  • Immunosuppressants (tacrolimus, cyclosporine): Caution
  • Beta-blockers and ACE inhibitors (metoprolol, lisinopril): Caution in possible sensitization
  • Tetracycline and quinolone antibiotics, levothyroxine, bisphosphonates (doxycycline, ciprofloxacin, alendronate): Monitor with calcium-containing products
  • Glucose-lowering drugs (metformin, insulin): Monitor
  • Thiazide diuretics (hydrochlorothiazide): Monitor with calcium supplements
  • NSAIDs (ibuprofen, aspirin): Caution in sensitized people
  • Calcium-containing antacids (calcium carbonate): Monitor
  • Calcium, vitamin D and vitamin K2 (calcium citrate, cholecalciferol): Monitor
  • Immune-stimulating supplements (beta-glucan, echinacea): Additive; caution in autoimmune disease
  • Prebiotic fibers (inulin): Additive to synergistic
  • Nattokinase (a clot-dissolving natto enzyme) and whole-natto extracts: Caution; added bleeding risk with anticoagulants (warfarin, apixaban)
  • Iron and zinc supplements (ferrous sulfate, zinc picolinate): Monitor
  • Edible jellyfish and γ-PGA cosmetics: Caution
  • HPV vaccination and cervical screening: Caution; complementary, not interchangeable

Risk & Side Effects

  • High:
  • Medium: Delayed-onset anaphylaxis
  • Low: Mild general complaints
  • Speculative: Autoimmune flare from immune stimulation; endotoxin and impurity contamination; mineral and drug binding in the gut

Monitoring

Marker Target Why
HbA1c 4.8–5.3% Long-term glucose control
Fasting glucose 75–90 mg/dL Baseline glycemia
LDL cholesterol Below 100 mg/dL Cholesterol signal
Serum calcium 9.2–10.0 mg/dL Hypercalcemia safety check
25-hydroxyvitamin D 40–60 ng/mL Calcium absorption depends on it
Bone mineral density (T-score) Above −1.0 Bone outcome of the calcium strategy
NK cell activity No established target; track change from own baseline Immune response marker
Cervical cytology and high-risk HPV Normal cytology and HPV-negative Lesion regression and viral clearance
Skin-prick or basophil activation test to γ-PGA Negative Allergy screen

Cadence: Symptom check at 1 week; labs at 8–12 weeks, then every 6–12 months during use; cervical cytology and HPV every 6–12 months for CIN 1 (low-grade precancerous cell changes); bone density after 1–2 years.

Qualitative Assessment

  • Bowel regularity: stool frequency and consistency
  • Delayed allergic symptoms: hives, itching, flushing or breathlessness 5–14 hours after a dose
  • Infection frequency: colds and respiratory infections per season
  • Energy and well-being: subjective vitality and daily energy
  • Mood: relaxed mood